Evidence map›Paper›PMID 31555883›Full record

ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2019

Atypical femur fracture incidence in women increases with duration of bisphosphonate exposure.

J C Lo, C D Grimsrud, S M Ott, M Chandra, R L Hui, B Ettinger

Abstract read
In one paragraph

Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Prevalence of incomplete atypical femoral fractures using single energy absorptiometry after long-term anti-resorptive therapy.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2025
    Article
  5. Article
  6. Latent metabolic bone disease, skeletal dysplasia and other conditions related to low bone formation among 38 patients with subtrochanteric femoral fractures: a retrospective observational study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024
    Observational
  7. Differences in bone histomorphometry between White postmenopausal women with and without atypical femoral fracture after long-term bisphosphonate therapy.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2024
    Article
  8. Article
  9. Identifying Complete Atypical Femur Fractures in Adults with Bisphosphonate Exposure.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2024
    Article
  10. Review
  11. Periprosthetic fractures: an unrecognized osteoporosis crisis.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2023
    Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Fracture Risk Following an Atypical Femoral Fracture.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2022
    Article
  19. Progression of atypical femur stress fracture after discontinuation of bisphosphonate therapy.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

J C LoDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA. Joan.C.Lo@kp.org.ORCID http://orcid.org/0000-0002-7159-0648
C D GrimsrudDepartment of Orthopedic Surgery, Kaiser Permanente Oakland Medical Center, 3600 Broadway, Oakland, CA, 94611, USA.
S M OttDepartment of Medicine, University of Washington School of Medicine, Seattle, WA, USA.
M ChandraDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA.
R L HuiPharmacy Outcomes Research Group, Kaiser Permanente California, 1800 Harrison Street, Oakland, CA, 94612, USA.
B EttingerDivision of Research, Kaiser Permanente Northern California, 2000 Broadway, Oakland, CA, 94612, USA.

Funding

Femur Fracture Outcomes Associated with Bisphosphonate UseR01AG047230 · NIA · KAISER FOUNDATION RESEARCH INSTITUTE · PI LO, JOAN C · 2015 to 2018
$2.3M
Kaiser Permanente Northern California Community Benefit Program n/aNIA NIH HHS R01 AG047230
6 · The paper itself

Abstract

In a northern California population of older women who were treated with oral bisphosphonate drugs, the incidence of atypical femur fracture, a rare complication of treatment, increased with longer duration of bisphosphonate exposure. These findings align with those previously reported in an independent southern California population.

introductionThe age-adjusted incidence of atypical femur fracture (AFF) reported in southern California increased with bisphosphonate (BP) exposure, ranging up to 113 per 100,000 person-years for 8-10-year exposure. This study examines the incidence of AFF in a northern California population.

methodsWomen age 45-89 years who initiated oral BP during 2002-2014 in Kaiser Permanente Northern California were followed for AFF outcome, defined by a primarily transverse diaphyseal femur fracture through both cortices, with focal periosteal/endosteal hypertrophy, minimal trauma, and minimal/no comminution. Total BP exposure was determined from dispensed prescriptions. The incidence of AFF, calculated for 2-year BP categories ranging from < 2 to > 10 years, was age-adjusted using the 2000 US Census.

resultsAmong 94,542 women, 107 experienced an AFF during or < 1 year after BP cessation (mean exposure 6.6 ± 3.0 years and total days' supply 5.7 ± 2.8 years at AFF). A strong relationship between AFF incidence and increasing BP exposure was seen, more than doubling for each 2-year category until 8-10 years. Among women with 2- to < 4-year BP, the crude and age-adjusted incidence was 18 and 9 per 100,000 person-years but increased over 2- and 5-fold for women with 4- to < 6- and 6- to < 8-year BP, respectively. For those receiving ≥ 8-year BP, the crude and age-adjusted incidence peaked at 196 and 112 per 100,000 person-years exposure.

conclusionIncidence of AFF increases markedly after 4-6 years of BP. These trends align with southern California and confirm a strong BP duration-related risk of this rare but serious event.

Indexed as

AgedAged, 80 and overBone Density Conservation AgentsCaliforniaDatabases, FactualDiphosphonatesDrug Administration ScheduleFemaleFemoral FracturesFractures, SpontaneousHumansIncidenceMiddle AgedRisk FactorsTime FactorsBone Density Conservation AgentsDiphosphonatesAtypical femur fractureBisphosphonateIncidence

Identifiers

PMID31555883
PMCPMC7449240

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.